|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for RPS29 |
 Gene summary |
| Basic gene Info. | Gene symbol | RPS29 |
| Gene name | ribosomal protein S29 | |
| Synonyms | DBA13|S29 | |
| Cytomap | UCSC genome browser: 14q | |
| Type of gene | protein-coding | |
| RefGenes | NM_001030001.2, NM_001032.4, | |
| Description | 40S ribosomal protein S29 | |
| Modification date | 20141219 | |
| dbXrefs | MIM : 603633 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000213741 | ||
| HPRD : 04698 | ||
| Vega : OTTHUMG00000140272 | ||
| Protein | UniProt: P62273 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_RPS29 | |
| BioGPS: 6235 | ||
| Pathway | NCI Pathway Interaction Database: RPS29 | |
| KEGG: RPS29 | ||
| REACTOME: RPS29 | ||
| Pathway Commons: RPS29 | ||
| Context | iHOP: RPS29 | |
| ligand binding site mutation search in PubMed: RPS29 | ||
| UCL Cancer Institute: RPS29 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for RPS29 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | Y7 | Y7C | KIRC | 1 | R22 | R22C | SKCM | 1 | S20 | S20C | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for RPS29 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | R22 | R22C | -1.2384979 | Y7 | Y7C | -0.74196896 | S20 | S20C | -0.55370927 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for RPS29 from PDB |
| Top |
| Differential gene expression and gene-gene network for RPS29 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for RPS29 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for RPS29 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of RPS29 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | NUC | Nucleic Acids | 2zkq | n | Y7 S20 | NUC | Nucleic Acids | 2zkq | n | Y7 S20 R22 |
| Top |
| Conservation information for LBS of RPS29 |
| Multiple alignments for P62273 in multiple species |
| LBS | AA sequence | # species | Species | C21 | QGSRSCRVCSN | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | C24 | RSCRVCSNRHG | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | C39 | YGLNMCRQCFR | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | C42 | NMCRQCFRQYA | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | G29 | CSNRHGLIRKY | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | K13 | WSHPRKFGQGS | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | L30 | SNRHGLIRKYG | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | M38 | KYGLNMCRQCF | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | N37 | RKYGLNMCRQC | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | Q41 | LNMCRQCFRQY | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | R19 | FGQGSRSCRVC | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | R22 | GSRSCRVCSNR | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | R27 | RVCSNRHGLIR | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | R40 | GLNMCRQCFRQ | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | S18 | KFGQGSRSCRV | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | S20 | GQGSRSCRVCS | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | V23 | SRSCRVCSNRH | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | Y7 | GHQQLYWSHPR | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |